BlueOcean NutraSciences Commences Commercialization of World’s First Omega-3 Shrimp Oil Products

TORONTO, ONTARIO--(Marketwired - Sept. 21, 2015) - BlueOcean NutraSciences (TSX VENTURE:BOC) ("BlueOcean" or the "Company"), a nutraceutical Company focused on developing specialty oils and extended release (XR) Omega-3 tablets from shrimp, fish, krill and algae oil for Health and Wellness markets, is pleased to announce that it has begun receiving orders from consumers via its online sales platform for its Pure Polar™ Omega-3 Shrimp Oil products. Pure Polar™ is the world's first omega-3 shrimp oil dietary supplement product line and is available in Regular Strength soft gels, Double Strength soft gels and Extended Release tablets. The Global market for Omega-3 supplements is estimated to be $4 Billion (Packaged Facts) and a shrimp oil alternative in the product category offers consumers a formulation containing high omega-3 EPA and DHA, high astaxanthin as well as phospholipids; a truly three-in-one product. The Company's Pure Polar™ XR Omega-3 extended release tablet was recently Named Among Top CPG Products for Innovation and Market Impact in Heart Health Supplements.

BlueOcean's Pure Polar™ Omega-3 Shrimp Oil formulations contain over two times more omega-3 EPA & DHA and 10 times more astaxanthin than typical retail krill oil brands, and contain phospholipids for better absorption of omega-3s. Product details and ordering can be found at:

www.purepolarshrimp.com

The products will also be available on Amazon, eBay and a number of other online sales outlets in the coming weeks.

About BlueOcean NutraSciences Inc.

BlueOcean NutraSciences Inc. is a Canadian listed public Company (TSX VENTURE:BOC) that is focused on developing sustainable, specialty nutraceutical oil products targeted at the rapidly growing Natural Astaxanthin, Omega-3 and Algal oil health and wellness markets.

BlueOcean and its JV partner, CMAX technologies, have developed a process to convert shrimp, krill, algae and other fish oils into Extended Release Tablets. BlueOcean owns 50% of the participating and voting rights in 2453969 Ontario Inc., a joint venture with CMAX Technologies that has developed the extended release omega-3/astaxanthin tablets.

The natural oils used in BlueOcean's products contain high levels of naturally occurring astaxanthin, phospholipids, and omega-3 EPA and DHA. Northern and Pacific AstaShrimp™ bulk oils are targeted at the high value and rapidly growing natural astaxanthin market. AlgaOmega™ oil is vegetarian, non-GMO omega-3 algal oil containing high levels of EPA with Polar Lipids and is targeted at the rapidly growing omega-3 algal oil ingredient market. Pure Polar™ Omega-3 Shrimp Oil products are targeted at the rapidly growing omega-3 and astaxanthin consumer dietary supplements markets.

Forward Looking Statements: BlueOcean

This news release may contain forward-looking statements that are based on BlueOcean's expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.